动物造模 z-bio 2022-07-25 368

　　Objective: To investigate the effect of miR-20b on airway inflammation in asthmatic mice.

　　Methods: BALB/c mice were randomly divided into normal control group, asthma group, asthma + miR-20b mimic treatment group, asthma + miR-20b mimic control treatment group. Ovalbumin (OVA) was sensitized and challenged to construct asthma model mice, and miR-20b mimics and their controls were administered via nasal drops. On the 49th day of the experimental procedure, the total number and differential count of cells in bronchoalveolar lavage fluid (BALF) were detected, the lung tissue was stained with HE to observe the pathological changes, and the concentration of vascular endothelial growth factor (VEGF) in BALF was detected by ELISA.

　　Results: After asthmatic mice were treated with miR-20b mimic, the total number of cells and the differential counts of neutrophils and eosinophils in BALF were significantly decreased (P<0.01), and the thickening of airway mucosa was reduced, and the airway lumen was reduced. Internal mucus secretion and peribronchial infiltration of inflammatory cells were reduced. Compared with the content of VEGF in the BALF of the asthma group, which was 28.55±3.42 pg/mL, the content of VEGF in the asthma+miR-20b mimic treatment group was significantly decreased (18.19±3.67 pg/mL) (P<0.01).

　　Conclusion: miR-20b inhibits airway inflammation in asthmatic mice, and this effect may be mediated by reducing the expression of VEGF.